Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma
June 17, 2019- BMC Cancer Lead Author: Noah Berlow, PhD
Cancer patients with advanced disease routinely exhaust available clinical regimens and lack actionable genomic medicine results, leaving a large patient population without effective treatments options when their disease inevitably progresses. To address the unmet clinical need for evidence-based therapy assignment when standard clinical approaches have failed, we have developed a probabilistic computational modeling approach which integrates molecular sequencing data with functional assay data to develop patient-specific combination cancer treatments.
Read the full publication at BMC Cancer here >>